A clinical trial to study the effect of Pankajakasthuri Breath Eazy Mishrit, in patients with cough, cold and breathing difficulties.

An open clinical trial for the assessment of efficacy of Pankajakasthuri Breath Eazy Mishrit in patients with Bronchial Asthma.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2016/10/007389

Enrollment

Registered

2016-10-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J454- Moderate persistent asthma Health Condition 2: J454- Moderate persistent asthma Health Condition 3: null- The Patients with Bronchial Asthma visiting PANKAJAKASTHURI AYURVEDA MEDICAL COLLEGE OUT PATIENT DEPARATMENTS for consultation.

Interventions

Intervention1: PANKAJAKASTHURI BREATH EAZY MISHRIT: DOSE : 20ML ROUTE OF ADMINISTRATION : ORAL FREQUENCY : THREE TIMES PER DAY TIME : AFTER FOOD Control Intervention1: NOT APPLICABLE: NOT APPLLICABLE

Eligibility

Inclusion criteria

Inclusion criteria: Both sex with equal distributor with or without rhinitis. 3 Mild persistent cases of Asthma (as per WHO GINA Guideline) of duration more than 6 months. Asthmatic meet reversibility criteria (15% improvement in FEVI after Beta â?? 2 agonist inhalation) 5

Exclusion criteria

Exclusion criteria: Mild intermittent, moderate persistent, severe persistent to severe Asthma (As per WHO GINA guidlines of duration more than 6 months) Dyspnoea due to other disease like Left ventricular failure, COPD (Chronic Bronchitis, Emphysema), Upper respiratory tract obstruction, Bronchiectasis, cases of tuberculosis, interstitial lung disease/occupational Lung disease, tropical pulmonary eosinophilia, Lofflers disease & Allergic Bronchopulmonary Aspergillosis etc. Diabetes Mellitus and Hypertension. Severe renal/Hepatic disease HIV positive cases Lung Cancer Pregnant/lactating mother Patient who need Salbutamol inhaler daily.

Design outcomes

Primary

Measure	Time frame
More than 70% of participants had 100% releif Percentage calculation and assessment criteria based on scoring of grading by using the following parameters. Frequency of swasa vega (Difficulty in respiration) 2Intensity and duration of attack 3Swasa krichrata (Dyspnoea) 4Ghurghurakam (Wheezing) 5Kaphashteevanam(Production of cough)Timepoint: SPECIFIC TIME FOR ASSESSING PRIMARY OUTCOME : 6 MONTHS	—

Secondary

Measure	Time frame
More than 70% of participants had 100% releif Percentage calculation and assessment criteria based on scoring of grading by using the following parameters. Frequency of swasa vega (Difficulty in respiration) 2Intensity and duration of attack 3Swasa krichrata (Dyspnoea) 4Ghurghurakam (Wheezing) 5Kaphashteevanam(Production of cough)Timepoint: SPECIFIC TIME FOR ASSESSING SECONDARY OUTCOME : 60 DAYS AND 90 DAYS	—

Measure

Time frame

More than 70% of participants had 100% releif Percentage calculation and assessment criteria based on scoring of grading by using the following parameters. Frequency of swasa vega (Difficulty in respiration) 2Intensity and duration of attack 3Swasa krichrata (Dyspnoea) 4Ghurghurakam (Wheezing) 5Kaphashteevanam(Production of cough)Timepoint: SPECIFIC TIME FOR ASSESSING SECONDARY OUTCOME : 60 DAYS AND 90 DAYS

—

Countries

India

Contacts

Public ContactDrSudhakumari

Pankajakasthuri Ayurveda Medical College and Post Graduate Centre

gssreekumarnair@gmail.com09486886362

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026